公开(公告)号：US20240034785A1

公开(公告)日：2024-02-01

申请号：US18256237

申请日：2020-12-07

申请人： NUCMITO PHARMACEUTICALS CO. LTD.

发明人： Xiaokun Zhang ,  Ying Su ,  Guobin Xie ,  Yuqi Zhou

IPC分类号： C07K16/28 ,  G01N33/574

CPC分类号： C07K16/28 ,  G01N33/57484 ,  G01N2333/70567

摘要： Provided herein are retinoid X receptor alpha binders that specifically bind to an epitope of a retinoid X receptor alpha, wherein the epitope comprises a phosphorylated serine at position 56 or 70. Also provided herein are retinoid X receptor alpha/polo-like kinase 1 modulators that inhibit the interaction of a polo-like kinase 1 with a retinoid X receptor alpha comprising a phosphorylated serine at position 56 or 70.

公开(公告)号：US20160274124A1

公开(公告)日：2016-09-22

申请号：US15174970

申请日：2016-06-06

申请人： Expression Pathology, Inc.

发明人： David B. KRIZMAN ,  Todd HEMBROUGH ,  Sheeno THYPARAMBIL ,  Wei-Li LIAO

IPC分类号： G01N33/68

CPC分类号： G01N33/6848 ,  G01N33/6893 ,  G01N33/743 ,  G01N2333/47 ,  G01N2333/70567 ,  G01N2800/56 ,  G01N2800/7028

摘要： The current disclosure provides specific peptides, and derived ionization characteristics of the peptides from the estrogen receptor (ER), progesterone receptor (PR), and/or antigen Ki67 (Ki67) proteins that are particularly advantageous for quantifying the ER, PR, and/or Ki67 proteins directly in biological samples that have been fixed in formalin by the method of Selected Reaction Monitoring/Multiple Reaction Monitoring (SRM/MRM) mass spectrometry. Such biological samples are chemically preserved and fixed wherein the biological sample is selected from tissues and cells treated with formaldehyde containing agents/fixatives including formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (FFPE) tissue/cells, FFPE tissue blocks and cells from those blocks, and tissue culture cells that have been formalin fixed and or paraffin embedded. A protein sample is prepared from a biological sample using the Liquid Tissue™ reagents and protocol, and the ER, PR, and/or Ki67 proteins are quantitated in the Liquid Tissue™ sample by the method of SRM/MRM mass spectrometry by quantitating in the protein sample at least one or more of the peptides described for one or more of the ER, PR, and/or Ki67 proteins. These peptides can be quantitated if they reside in a modified or in an unmodified form. An example of a modified form of an ER, PR, and/or Ki67 peptide is phosphorylation of a tyrosine, threonine, serine, and/or other amino acid residues within the peptide sequence.

摘要翻译： 目前的公开内容提供特异性肽，以及来自雌激素受体（ER），孕酮受体（PR）和/或抗原Ki67（Ki67）蛋白质的肽的衍生电离特征，其特别有利于定量ER，PR和/ 或通过选择反应监测/多反应监测（SRM / MRM）质谱法的方法在已经在福尔马林中固定的生物样品中直接存在Ki67蛋白。 这些生物样品被化学保存和固定，其中生物样品选自用含甲醛的试剂/固定剂（包括福尔马林固定的组织/细胞，福尔马林固定/石蜡包埋的（FFPE）组织/细胞，FFPE组织块）和 来自这些区块的细胞和已被福尔马林固定和石蜡包埋的组织培养细胞。 使用Liquid Tissue TM试剂和方案从生物样品制备蛋白质样品，并通过SRM / MRM质谱法的方法在液体组织样品中定量分析ER，PR和/或Ki67蛋白质， 蛋白质样品至少一种或多种针对一种或多种ER，PR和/或Ki67蛋白质描述的肽。 如果它们以修饰或未修饰的形式存在，则可以定量这些肽。 ER，PR和/或Ki67肽的修饰形式的实例是肽序列内的酪氨酸，苏氨酸，丝氨酸和/或其他氨基酸残基的磷酸化。

公开(公告)号：US20160033531A1

公开(公告)日：2016-02-04

申请号：US14773901

申请日：2014-03-15

申请人： ST. JUDE CHILDREN'S RESEARCH HOSPITAL

发明人： Taosheng Chen ,  Wenwei Lin

IPC分类号： G01N33/68 ,  G01N21/64

CPC分类号： G01N33/6875 ,  G01N21/6428 ,  G01N33/542 ,  G01N33/566 ,  G01N33/582 ,  G01N2021/6439 ,  G01N2333/70567 ,  G01N2500/04 ,  G01N2500/20

摘要： In one aspect, the invention relates to compounds useful as fluorescence assay probes, methods of making same, and methods of using same to assay ligand binding interactions with PXR. In various aspects, the invention pertains to compositions comprising a polypeptide comprising a pregnane X receptor polypeptide, or a ligand binding fragment polypeptide thereof; and a molecule comprising a BODIPY residue and a vinca alkaloid residue. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

摘要翻译： 一方面，本发明涉及可用作荧光测定探针的化合物，其制备方法，以及使用该化合物测定与PXR的配体结合相互作用的方法。 在各个方面，本发明涉及包含含有孕烷X受体多肽或其配体结合片段多肽的多肽的组合物; 和包含BODIPY残基和长春花生物碱残基的分子。 该摘要旨在作为用于在特定技术中进行搜索的扫描工具，而不意在限制本发明。

公开(公告)号：US20160025746A1

公开(公告)日：2016-01-28

申请号：US14852623

申请日：2015-09-13

申请人： Regen BioPharma, Inc

发明人： Christine Victoria Ichim

IPC分类号： G01N33/68

CPC分类号： G01N33/6875 ,  A61K31/427 ,  G01N33/57426 ,  G01N33/6872 ,  G01N2333/70567 ,  G01N2500/04 ,  G01N2800/22 ,  Y02A50/473

摘要： The current invention discloses compositions of matter, protocols and methods of screening test compounds to identifying agonists and antagonists of the orphan nuclear receptor NR2F6 by measuring the ability of a test compound to occupy the active site of NR2F6, in the presence of a reference compound.

摘要翻译： 本发明公开了在参考化合物存在下，通过测量测试化合物占据NR2F6的活性位点的能力来筛选测试化合物以识别孤儿核受体NR2F6的激动剂和拮抗剂的组合物，方案和方法。

公开(公告)号：US20150299712A1

公开(公告)日：2015-10-22

申请号：US14595078

申请日：2015-01-12

申请人： Christine Victoria Ichim ,  Tom Ichim

发明人： Christine Victoria Ichim ,  Tom Ichim

IPC分类号： C12N15/113

CPC分类号： C12N15/1138 ,  A61K31/7105 ,  A61K31/713 ,  C12N2310/11 ,  C12N2310/531 ,  C12N2320/30 ,  G01N33/57426 ,  G01N33/6875 ,  G01N2333/70567 ,  G01N2800/22

摘要： The invention provides means of manipulating hematopoietic stem cell differentiation by modulation of levels of NR2F6 (EAR2). Provided are compositions of matter, protocols and methods of use by which inhibiting expression of NR2F6 or activity thereof promotes differentiation of selective hematopoietic lineages, or conversely overexpression of NR2F6 or activity thereof inhibits differentiation. In one embodiment inhibition of differentiation is performed in other cell lineages besides hematopoietic.

摘要翻译： 本发明提供了通过调节NR2F6（EAR2）水平来操纵造血干细胞分化的方法。 提供了抑制NR2F6的表达或其活性促进选择性造血谱系分化的物质，方案和使用方法的组合物，或者NR2F6的过度表达或其活性抑制分化。 在一个实施方案中，在除造血之外的其他细胞谱系中进行分化的抑制。

公开(公告)号：US20150297627A1

公开(公告)日：2015-10-22

申请号：US14588373

申请日：2014-12-31

申请人： Christine Victoria Ichim

发明人： Christine Victoria Ichim

IPC分类号： A61K31/713 ,  A61K9/127 ,  A61K31/7105 ,  C12N15/113 ,  A61K45/06

CPC分类号： A61K31/713 ,  A61K9/127 ,  A61K31/7088 ,  A61K31/7105 ,  A61K45/06 ,  C12N15/1138 ,  C12N2310/11 ,  C12N2310/531 ,  C12N2320/30 ,  G01N33/57426 ,  G01N33/6875 ,  G01N2333/70567 ,  G01N2800/22

摘要： The current invention discloses compositions of matter, protocols and methods of use of treatment for cancer and other diseases of aberrant cellular proliferation and differentiation by inhibiting expression of NR2F2 or activity thereof. In one embodiment, administration of synthetic oligonucleotides that induce RNA interference mediated degradation of the nuclear receptor NR2F2 in human or animal patients is performed at a sufficient concentration or frequency to achieve regression of tumor.

摘要翻译： 本发明公开了通过抑制NR2F2的表达或其活性来治疗癌症和异常细胞增殖和分化的其它疾病的物质组合物，方案和方法。 在一个实施方案中，以足够的浓度或频率进行诱导人或动物患者中核受体NR2F2的RNA干扰介导的降解的合成寡核苷酸的施用以实现肿瘤消退。

公开(公告)号：US20150291964A1

公开(公告)日：2015-10-15

申请号：US14571262

申请日：2014-12-15

申请人： Christine Victoria Ichim

发明人： Christine Victoria Ichim

IPC分类号： C12N15/113 ,  A61K45/06 ,  A61K31/7088

CPC分类号： C12N15/1138 ,  A61K31/7088 ,  A61K31/7105 ,  A61K31/713 ,  A61K45/06 ,  C12N2310/11 ,  C12N2310/14 ,  G01N33/57426 ,  G01N33/6875 ,  G01N2333/70567 ,  G01N2800/22

摘要： The current invention discloses compositions of matter, protocols and methods of use of treatment for cancer and other diseases of aberrant cellular proliferation and differentiation by inhibiting expression of NR2F6 or activity thereof. In one embodiment, administration of synthetic oligonucleotides that induce RNA interference mediated degradation of the nuclear receptor NR2F6 in human or animal patients is performed at a sufficient concentration or frequency to achieve regression of tumor.

摘要翻译： 本发明公开了通过抑制NR2F6的表达或其活性来治疗癌症和异常细胞增殖和分化的其它疾病的物质组合物，方案和方法。 在一个实施方案中，以足够的浓度或频率进行诱导人或动物患者中诱导RNA干扰介导的核受体NR2F6降解的合成寡核苷酸的实施以实现肿瘤消退。

公开(公告)号：US20150241448A1

公开(公告)日：2015-08-27

申请号：US14689820

申请日：2015-04-17

申请人： JOSEP BASSAGANYA-RIERA ,  PINYI LU ,  RAQUEL HONTECILLAS

发明人： JOSEP BASSAGANYA-RIERA ,  PINYI LU ,  RAQUEL HONTECILLAS

IPC分类号： G01N33/68 ,  G06F19/16 ,  G06F19/00 ,  G06F19/12

CPC分类号： G01N33/6872 ,  A61K31/13 ,  A61K31/135 ,  A61K31/35 ,  A61K31/352 ,  A61K31/40 ,  A61K31/405 ,  A61K31/4184 ,  A61K31/427 ,  A61K31/431 ,  A61K31/495 ,  A61K31/496 ,  A61K31/4985 ,  A61K31/517 ,  A61K31/545 ,  A61K31/55 ,  A61K31/56 ,  A61K31/57 ,  A61K31/65 ,  A61K31/655 ,  A61K31/704 ,  A61K31/7048 ,  G01N33/573 ,  G01N33/6875 ,  G01N2333/4703 ,  G01N2333/70567 ,  G01N2500/02 ,  G01N2500/04 ,  G01N2500/20 ,  G06F19/3456 ,  G16B5/00 ,  G16B15/00 ,  Y02A90/26 ,  Y10T436/143333 ,  Y10T436/145555 ,  Y10T436/147777 ,  A61K2300/00

摘要： The present invention relates to the field of medical treatments for diseases and disorders. More specifically, the present invention relates to the use of the lanthionine synthetase component C-like (LANCL) proteins as therapeutic targets for novel classes of anti-inflammatory, immune regulatory and antidiabetic drugs. This includes but it is not limited to abscisic acid (ABA), ABA analogs, benzimidazophenyls, repurposed drugs or drug combinations, including thiazolidinediones (TZDs); naturally occurring compounds such as conjugated diene fatty acids, conjugated triene fatty acids, isoprenoids, and natural and synthetic agonists of peroxisome proliferator-activated receptors that activate this receptor through an alternative mechanism of action involving LANCL2 or other membrane proteins to treat or prevent the common inflammatory pathogenesis underlying type 2 diabetes, atherosclerosis, cancer, some inflammatory infectious diseases such as influenza and autoimmune diseases including but not limited to inflammatory bowel disease (Crohn's disease and Ulcerative colitis), rheumatoid arthritis, multiple sclerosis and type 1 diabetes and other chronic inflammatory conditions.

摘要翻译： 本发明涉及疾病和病症的医疗治疗领域。 更具体地说，本发明涉及甲硫氨酸合成酶组分C样（LANCL）蛋白作为新型抗炎，免疫调节和抗糖尿病药物的治疗靶标的用途。 这包括但不限于脱落酸（ABA），ABA类似物，苯并咪唑苯基，重用药物或药物组合，包括噻唑烷二酮类（TZD）; 天然存在的化合物，例如共轭二烯脂肪酸，共轭三烯脂肪酸，类异戊二烯，以及过氧化物酶体增殖物激活受体的天然和合成激动剂，其通过涉及LANCL2或其它膜蛋白的另一种作用机制来活化该受体，以治疗或预防共同 潜在的2型糖尿病，动脉粥样硬化，癌症，一些炎性传染病如流感和自身免疫疾病，包括但不限于炎症性肠病（克罗恩病和溃疡性结肠炎），类风湿性关节炎，多发性硬化和1型糖尿病等慢性炎症 条件。

公开(公告)号：US09091696B2

公开(公告)日：2015-07-28

申请号：US13652395

申请日：2012-10-15

申请人： Christine Victoria Ichim ,  Richard Alexander Wells

发明人： Christine Victoria Ichim ,  Richard Alexander Wells

IPC分类号： A61K38/00 ,  C12N15/63 ,  G01N33/68 ,  A61K31/00 ,  A61K31/7088 ,  G01N33/574

CPC分类号： G01N33/6872 ,  A61K31/00 ,  A61K31/7088 ,  G01N33/57426 ,  G01N33/6875 ,  G01N2333/70567 ,  G01N2800/22

摘要： The application provides methods of modulating NR2F6 in a cell or animal in need thereof by administering an effective amount of a NR2F6 modulator.

摘要翻译： 本申请提供了通过施用有效量的NR2F6调节剂在有需要的细胞或动物中调节NR2F6的方法。

公开(公告)号：US20130183668A1

公开(公告)日：2013-07-18

申请号：US13667832

申请日：2012-11-02

申请人： Derek Mann ,  Jelena Mann ,  Mujdat Zeybal

发明人： Derek Mann ,  Jelena Mann ,  Mujdat Zeybal

IPC分类号： C12Q1/68

CPC分类号： C12Q1/6883 ,  C12Q2600/106 ,  C12Q2600/112 ,  C12Q2600/154 ,  C12Q2600/156 ,  C12Q2600/158 ,  G01N2333/70567 ,  G01N2800/085 ,  G01N2800/56

摘要： The present invention relates to methods for identifying susceptibility of impaired hepatic wound healing in a patient, most particularly by identifying modifications of the of PPAR-γ and TGFβ1 genes. It further relates to stratifying populations of patients to determine susceptibility to impaired hepatic wound healing and direct appropriate healthcare resources. More specifically methods can be used to stratify liver disease patient populations to identify those most likely to progress to cirrhosis, or to identify the likelihood that a patient with liver disease will progress to having cirrhosis.

摘要翻译： 本发明涉及鉴别患者肝损伤愈合易感性的方法，特别是通过鉴定PPAR-γ和TGFbeta1基因的修饰。 它进一步涉及分层的患者群体，以确定肝损伤愈合受损的易感性和直接适当的保健资源。 更具体地，可以使用方法来分层肝病患者群体，以鉴定最可能进展为肝硬化的那些，或者确定肝病患者进展为肝硬化的可能性。